Overview of Viscid-OD

Quick Facts

Property	Description
Active ingredient	Domperidone and Omeprazole
Form	Capsule
Pharmacological class	Prokinetic agent and Proton Pump Inhibitor (PPI) combination
Common use	Relief of symptoms associated with acidity and impaired gastric emptying
Origin	Synthetic chemical substances

Viscid-OD is a prescription medicine delivered as an oral capsule that functions as an anti-reflux medicine by integrating two distinct pharmacological approaches into a single preparation. The medicine is classified as a fixed-dose combination of a Prokinetic agent and a Proton Pump Inhibitor (PPI). This strategy is clinically recognized for its ability to address both chemical hyperacidity and the mechanical dysfunction of the upper digestive system, distinguishing it from therapies that rely on a single mechanism.

What Type of Medicine is Viscid-OD?

Viscid-OD is defined as a combination medicine that unites two separate active ingredients with complementary actions, intended to comprehensively manage symptoms like heartburn and nausea. This structure is employed to simultaneously address both excessive acid and slow digestive movement. For patients seeking this dual mechanism, similar generic formulations may be available, such as Domstal Plus or Mexopal D, although the specific excipients and manufacturing processes vary by brand.

Composition and General Purpose

The Viscid-OD formulation contains the active ingredients (INN) Omeprazole and Domperidone, which are both synthetic chemical substances. Omeprazole acts as a potent antisecretory compound, and its role as a Proton Pump Inhibitor is described in pharmacological studies. This component is designed to achieve sustained Gastric Acid Reduction. Conversely, Domperidone acts as a dopamine antagonist and prokinetic drug to promote gastric emptying. Therefore, the medicine's general purpose is to provide simultaneous relief from the physical discomfort of slow clearance and the chemical injury caused by acid reflux.

Regulatory References

Omeprazole: MedlinePlus Drug Information

What side effects are possible with Viscid-OD?

Possible Side Effects and Safety Information

Viscid-OD (omeprazole and domperidone) has an established safety profile with documented adverse reactions primarily affecting the gastrointestinal and nervous systems. This information is derived from official governmental regulatory documents.

Common Adverse Reactions

The most commonly reported side effects (affecting up to 1 in 10 people) include:

Gastrointestinal: Diarrhea, flatulence, stomach pain, fundic gland polyps.
Nervous System: Headache, dizziness, drowsiness.
General: Dry mouth, weakness.

Serious and Clinically Significant Risks

While uncommon, serious adverse reactions have been documented. The most significant risk associated with the domperidone component is the increased potential for irregular heartbeat (serious arrhythmias), particularly in patients aged 60 years and older or those receiving doses exceeding established limits. Long-term use (over a year) may also require monitoring of blood magnesium levels and is associated with a possible risk of bone weakening.

Contraindications and Safety Limitations

Viscid-OD is strictly contraindicated in several specific situations due to safety concerns:

Known hypersensitivity to omeprazole, domperidone, or any related components.
Pre-existing heart conditions, including certain heart failure states, heart rhythm problems, or electrolyte imbalances.
Active gastrointestinal bleeding, obstruction, or perforation.
Patients with severe liver impairment should avoid use, and use is not recommended for children under 18 years.

Caution is advised for activities requiring concentration, such as driving or operating machinery, due to the potential for drowsiness or dizziness. Safety notes also emphasize the importance of monitoring blood levels of potassium, magnesium, and calcium, and review of all concurrent medications, especially antiarrhythmics and agents that prolong the QT interval.

Overdose and Emergency Response

The official regulatory documentation for the components of Viscid-OD outlines specific manifestations and emergency procedures for overdose. Overdose presentations primarily involve the Central Nervous System (CNS), with documented symptoms including disorientation, confusion, dizziness, drowsiness, and difficulty in speaking. Uncontrolled movements (extrapyramidal symptoms) and seizures have also been reported, with extrapyramidal symptoms noted to be more likely to occur in children.

The most serious outcomes are tied to the Cardiovascular System, including the documented risk of prolongation of the QT interval, serious ventricular arrhythmias (such as Torsades de pointes), cardiac arrest, and sudden cardiac death. Due to this documented cardiac risk, regulatory authorities mandate that ECG monitoring should be undertaken in all cases of suspected overdose. The elimination half-life is noted to be prolonged in patients with severe renal impairment.

In the event of an overdose, an immediate action is required: individuals must seek medical attention straight away or contact a Poison Control Center. If any signs or symptoms associated with a cardiac arrhythmia occur, the medication must be stopped immediately. Management is confined to standard symptomatic and supportive treatment, as no specific antidote is officially documented.

Therapeutic Uses of Viscid-OD

What Viscid-OD Treats: Main Uses and Benefits

Viscid-OD is a combination medication used to address upper gastrointestinal symptoms associated with conditions such as Gastroesophageal Reflux Disease (GERD) and functional dyspepsia. It is commonly applied in clinical settings that involve acute or unstable symptom patterns, which may help support symptomatic comfort during these episodes.

The medication is designed to address symptoms related to stomach acid production, such as heartburn and acid regurgitation, and also provides support in addressing motility-related symptoms like nausea, bloating, and a persistent feeling of fullness after meals. Domperidone is indicated for use in conditions including nausea, vomiting, and dyspepsia.

The combined formulation is applied in scenarios where additional management of discomfort is required. It may assist with maintaining functional stability and supports patients during episodes of heightened discomfort.

“The medicine is considered relevant for easing symptom clusters that may become intense or disruptive.”

Quick Fact: Relief for Nausea and Acid-Related Symptoms

Regulatory References

Health Sciences Authority advisory on Domperidone

Eligibility and Restrictions for Use

Who Can and Cannot Use Viscid-OD?

Eligibility for Viscid-OD is defined by official regulatory documentation, focusing on contraindications, age limits, and pre-existing medical conditions.

Contraindicated Populations (Must Not Use)

Viscid-OD is strictly contraindicated for use in specific populations as stated in labeling:

Patients with known hypersensitivity to omeprazole, domperidone, or related compounds.
Individuals with moderate or severe hepatic impairment (liver dysfunction).
Those with known existing prolongation of cardiac conduction intervals (QTc) or underlying cardiac diseases, such as congestive heart failure.
Patients with prolactin-releasing pituitary tumours (prolactinoma).
Use is prohibited when the medicine is taken concurrently with potent CYP3A4 inhibitors or other QT-prolonging medicines.

Population Restrictions

Category	Regulatory Status
Age (Pediatric)	Not recommended for children under 12 years of age or those weighing less than 35 kg; it is approved for adolescents 12 years and older weighing ge 35 kg.
Renal Impairment	Patients with severe renal impairment require restricted use, often involving a reduced Domperidone dosing frequency.
Pregnancy/Lactation	Restricted/Conditional use. Use during pregnancy is conditional. Use during breastfeeding is cautioned as cardiac effects in the infant cannot be excluded.
Comorbidity (GI)	Contraindicated if stimulation of motility is harmful, such as in cases of gastro-intestinal haemorrhage or perforation. Before treatment, malignancy must be excluded in patients with alarm symptoms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for this medicine is structured around the distinct interaction patterns of its two active ingredients. The Domperidone component carries several absolute contraindications. Co-administration with potent or moderate CYP3A4 inhibitors (such as certain macrolide antibiotics and azole antifungals) is prohibited because this interaction significantly increases Domperidone’s plasma concentration. This elevated systemic exposure is associated with an increased risk of QT prolongation and serious ventricular arrhythmias.

For the same pharmacodynamic reason, combining this medicine with any other drug formally known to prolong the QT interval is also contraindicated. The Domperidone component is also contraindicated for use in patients with pre-existing moderate or severe hepatic impairment due to risks related to altered drug clearance.

The Omeprazole component is primarily involved in pharmacokinetic interactions. It functions as an inhibitor of the CYP2C19 enzyme, which can reduce the antiplatelet activity of Clopidogrel or increase the systemic exposure of other substrates, including Warfarin and Tacrolimus. Furthermore, Omeprazole’s inhibition of gastric acid secretion interferes with the absorption of medicinal products that require an acidic stomach environment, resulting in a reduced plasma concentration of certain antiretrovirals (e.g., Atazanavir, Nelfinavir) and antimicrobials. Co-administration with strong CYP inducers like Rifampin or the herbal product St. John’s Wort is cautioned against, as this can reduce Omeprazole concentrations.

Mechanism of Action

Mechanism of Action: Viscid-OD

Viscid-OD initiates its effect through selective binding to a specific subset of regulatory receptors or enzymes within the cellular communication systems. This high-affinity molecular targeting acts as the primary mechanistic focus, determining the drug's precise influence on targeted cells by acting to initiate or block specific signaling events.

Once bound, Viscid-OD modulates activity within defined neural or humoral signaling pathways by limiting the production of downstream chemical messengers. This mechanistic cascade is applied in contexts involving heightened pathway activation to modulate overactive or dysregulated physiological processes.

By controlling the signal flow through these key pathways, Viscid-OD ultimately modifies or dampens excessive signaling within central and/or peripheral systems. This targeted effect on key regulatory systems modifies the rate of firing within overactive physiological responses, resulting in a system-level physiological modulation that shapes the drug's effect profile.

Dosage and Administration Information

How to Use Viscid-OD

This section describes the administration and dosing patterns for Viscid-OD, a fixed-dose combination medicine containing omeprazole and domperidone.

Administration Scope

Instruction	Detail
Route of administration	The medicine is strictly for the oral route (by mouth).
Dosing schedule	The standard adult regimen is one capsule once daily.
Timing in relation to meals	The capsule must be taken before a meal, specifically 30 to 60 minutes prior to the morning meal, typically on an empty stomach.
Preparation requirements	The capsule must be swallowed whole with water; it must not be crushed, chewed, or broken.
Population-specific conditions	Dose adjustments or special considerations are required for patients with hepatic impairment (liver dysfunction) and severe renal impairment (kidney dysfunction).

General Use Protocol

Viscid-OD is intended for a short-term treatment course only, with defined limits, typically not exceeding 4 weeks. The recommended pattern of taking the medicine once daily before a meal is intended to allow the active ingredients to be absorbed according to their design. If a dose is missed, a patient is generally advised to resume the regular schedule and is cautioned against taking a double dose to compensate. This structure of timing and duration defines the standardized use of this combination product.

Recent Clinical Evidence

Research evidence / Overview of studies for Viscid-OD

This overview summarizes the research conducted to evaluate the Omeprazole and Domperidone combination, focusing on the types of studies available and the outcomes they monitored. This information is based solely on clinical trial reports and regulatory findings.

Evidence for use in Gastroesophageal Reflux Disease (GERD)

Research exploring outcomes related to Gastroesophageal Reflux Disease (GERD) was primarily conducted using short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. Many studies included Omeprazole monotherapy as a comparator arm and measured both Patient-Reported Outcomes (PROs), such as heartburn frequency, and the status of esophageal healing. Studies described patterns of measurement indicating that overall global symptom change was tracked in the combination group. However, certainty remains low; long-term outcomes and consistency in Quality of Life measurements are not fully established in large-scale studies.

Evidence for use in Functional Dyspepsia and Motility Symptoms

Research explored the combination in studies involving conditions where outcomes related to functional imbalance were measured, such as Functional Dyspepsia. Studies, including RCTs and observational reviews, monitored symptoms like nausea, bloating, and early satiety, alongside assessing the state of the stomach lining. Reports documented patterns that included how symptoms evolved in the observed populations. A significant research limitation is that many studies rely on open-label designs or data from specific regional populations, which can limit the generalizability of the findings.

Long-Term Studies and Durability of Response

Most foundational research involves short-to-intermediate follow-up durations, typically ranging from 4 to 16 weeks. Evidence is limited for long-term outcomes, as follow-up durations were restricted in the primary trials, and the durability of symptom relief is not fully established.

Evidence in Specific Patient Populations

Studies included specific populations, such as adults with co-existing conditions like asthma and Type 2 Diabetes Mellitus, where outcomes related to acid and motility were evaluated. However, data for certain groups, including children and patients using specific anti-diabetic medications, remains insufficient.

Gaps and Uncertainties in the Research Landscape

The evidence highlights what is known, but certainty remains low in several areas. Evidence quality varies across studies, and some findings, such as those related to atypical reflux manifestations like Laryngopharyngeal Reflux (LPR), have been reported as mixed or inconclusive. Further comparative research is needed to understand all facets of symptom management.

Key Studies & References

Adverse Drug Reaction News Bulletin (May 2017) – Focus on Domperidone

Frequently Asked Questions (FAQ)

Common questions about Viscid-OD (FAQ)

Q: Is Viscid-OD the same as the regular version of the drug, or is it different?

A: Viscid-OD is defined in official documents as a fixed-dose combination product. It contains two active ingredients: omeprazole (an acid reducer) and domperidone (for stomach movement). The 'OD' generally indicates an once-daily formulation, which is designed to provide sustained action and differs from separate, standard, immediate-release versions of the individual medicines.

Q: How quickly can a person generally expect Viscid-OD to start working?

A: Official information describes the omeprazole component, which is an acid reducer, as potentially having a rapid start to its effect. However, it can typically take 1 to 4 days of continued use to achieve the full acid-suppressing benefit and noticeable symptom relief, which is generally consistent with this class of medicine.

Q: What is the time frame for the effects of Viscid-OD to last?

A: Viscid-OD is a once-daily formulation, according to regulatory documents. This indicates the medicine is specifically designed to be taken one time every 24 hours to provide a sustained effect on both stomach acid and digestive movement throughout the day.

Q: Are there common stomach problems associated with Viscid-OD?

A: Official safety documents indicate that commonly reported side effects affecting the stomach and digestive system include diarrhea, flatulence (gas), and stomach pain. The official safety profile also includes clinically significant risks, such as gastrointestinal bleeding, which are often listed as contraindications for use.

Q: Can Viscid-OD interact with common over-the-counter pain relievers?

A: The omeprazole component is known to interact with various medicines by affecting how they are absorbed or processed by the body. Because other medicines may affect the gastric lining, regulatory information advises that all concurrent treatments, including those bought without a prescription, should be reviewed by a healthcare provider.

Q: Are there any known issues with drinking alcohol while taking Viscid-OD?

A: Official safety information includes statements cautioning against the consumption of alcohol while taking this combination medicine. Alcohol may stimulate the production of stomach acid, which could potentially worsen the symptoms the medicine is intended to manage.

Q: Is Viscid-OD safe to take if I have liver concerns?

A: Viscid-OD is strictly contraindicated (meaning its use is prohibited) in individuals with moderate or severe hepatic impairment, which is significant liver dysfunction. For those with milder liver concerns, use requires specific guidance from a healthcare provider, according to regulatory notes.

Q: Can Viscid-OD interact with prescription medications for mood or anxiety?

A: The omeprazole component can interact with medicines that are metabolized (broken down) by certain liver enzymes. Because some mood and anxiety medicines, such as diazepam, use these same enzyme pathways, regulatory documents indicate that any concurrent prescription medicines should be carefully reviewed by a healthcare provider.

Q: Can Viscid-OD affect blood pressure?

A: Official safety documents focus on the medicine’s association with heart rhythm changes. The medicine is contraindicated in patients with pre-existing heart conditions, including certain heart rhythm problems, because the domperidone component is associated with an increased risk of serious irregular heartbeats (arrhythmias).

Q: What happens if I miss a scheduled time to take Viscid-OD?

A: Official use documents state that if a dose is missed, taking a double dose to compensate is not the instructed procedure. The individual should resume the regular schedule with the next planned dose at its usual time.

Q: What is the ingredient name for the active drug in Viscid-OD?

A: The Viscid-OD formulation is a combination of two separate active ingredients: Omeprazole and Domperidone. Official regulatory documents classify these as a Proton Pump Inhibitor (PPI) and a Prokinetic agent, respectively.

Q: Does the 'OD' formulation mean it is designed to release slowly?

A: The 'OD' in the name typically means Once Daily, indicating the medicine is dosed one time per day. The formulation is often described as a delayed-release capsule, meaning the ingredients are protected from stomach acid and designed to be released later for a sustained effect.

Q: Are there specific warnings about driving or operating machinery while using Viscid-OD?

A: Official safety information includes statements cautioning about activities that require high levels of concentration, such as driving or operating machinery. This is due to the potential for side effects reported in official documents, including drowsiness or dizziness.

Q: What is known about Viscid-OD and breastfeeding?

A: Use of Viscid-OD during breastfeeding is considered restricted or conditional. Official product labeling advises caution because effects on the infant’s heart cannot be excluded due to the domperidone component. A careful risk-benefit determination by a healthcare provider is noted as being required for use during this period.

Q: Why is Viscid-OD available in different strengths?

A: According to official regulatory guidance, medicines are generally available in different strengths to allow for the selection of an appropriate dose based on specific treatment needs, symptom severity, and official guidelines. This variation helps align the dose with the patient's prescribed regimen.

Q: How does Viscid-OD get eliminated from the body?

A: Official pharmacological data indicates that the omeprazole component is primarily processed (metabolized) by the liver and then mostly excreted in the urine. The clearance of the domperidone component is significantly impacted in people with severe kidney issues.

Q: What kind of monitoring is typically done when a person starts taking Viscid-OD?

A: Official warnings and safety information emphasize the importance of monitoring blood levels of certain electrolytes, such as potassium, magnesium, and calcium, in some patients. Regulatory warnings indicate that a healthcare provider’s review of all other concurrent medicines, especially those that affect heart rhythm, is important.

How should Viscid-OD be stored and disposed of?

The storage and disposal of Viscid-OD must strictly comply with official regulatory labeling to ensure product quality and environmental safety.

Required Storage Conditions

Viscid-OD capsules require storage at controlled room temperature, typically below 25 C to 30 C. The medicine must be protected from light and moisture and should remain in its original container with the lid tightly closed. It is specifically mandated not to refrigerate or freeze the product, as this can compromise its stability. Like all prescription medicines, Viscid-OD must be kept out of the sight and reach of children.

Official Disposal Instructions

Expired or unused Viscid-OD must not be thrown away in household trash or discarded via wastewater (sinks or toilets). The proper procedure for disposal is to consult with a pharmacist or utilize official drug take-back programs or community collection points, adhering to local pharmaceutical waste regulations.

Viscid-OD